BRCA Mutations in Latinas
Summary
Background:
- BRCA1 and BRCA2 gene mutations have been linked to a higher risk of developing breast cancer and other cancers, and may be associated with types of breast cancer that are more difficult to treat and more likely to recur. New cancer treatments are being developed specifically to treat individuals who have these gene mutations. However, more information is needed about the prevalence of these mutations in minority populations, including Hispanic/Latino populations. To study these populations, researchers are interested in collecting genetic material (DNA) and medical history information from Hispanic/Latino women who have been diagnosed with breast cancer.
Objectives:
- To collect saliva samples and medical and family history information from Hispanic/Latino women with breast cancer.
Eligibility:
- Hispanic/Latino women at least 18 years of age who have been diagnosed with breast cancer.
Design:
- Participants will complete a questionnaire with information about place of birth, languages spoken by parents and grandparents, and information about their breast cancer diagnosis.
- Participants will provide a saliva sample (2 to 3 tablespoons) for analysis.
- No treatment will be provided as part of this protocol.
Description
BACKGROUND:
- Mutations in the BRCA1 and BRCA2 genes predispose to breast and ovarian cancer, and are increasingly recognized in prostate and pancreatic cancers.
- Basal/ Triple negative breast cancer is associated with BRCA mutations in some ethnicities.However the link between BRCA gene mutations and Basil/ triple negative disease in Hispanic/ Latino women is not known.
- Common recurrent mutations in BRCA1 and BRCA2 exist in Hispanic/ Latino communities.
- New therapies such as PARP inhibitors may be particularly effective in BRCA mutation carriers.
- Therefore a unique opportunity exists to identify women in this underserved minority that may be eligible for and benefit from new targeted therapies.
OBJECTIVES:
- The primary objective is to collect saliva samples and histology data from up to 2000 Hispanic/ Latino subjects with breast cancer as a source of DNA, and to analyze the BRCA1 and BRCA2 genes..
ELIGIBILITY:
- All Hispanics females, over the age of 18, with breast cancer will be eligible.
DESIGN:
- Natural history study of 2000 Hispanic/Latino women with breast cancer, 1000 with triple
negative disease, 1000 without.
- Obtain clinical pathology reports and relevant history data on all subjects.
- Analyze recurrent BRCA1 and BRCA2 mutations
Study Design
N/A
Conditions
Breast Neoplasms
Location
Southwest Cancer Treatment and Research Center, Lubbock; Texas Tech University
Lubbock
Texas
United States
79415
Status
Recruiting
Source
National Institutes of Health Clinical Center (CC)
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01251900
- Information obtained from ClinicalTrials.gov on May 23, 2013
Medical and Biotech [MESH] Definitions
Breast Neoplasms, Male
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
Neoplasms, Ductal, Lobular, And Medullary
Neoplasms, usually carcinoma, located within the center of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. Most cancers of this type are located in the breast.
Inflammatory Breast Neoplasms
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
Breast Neoplasms
Tumors or cancer of the human BREAST.
Ultrasonography, Mammary
Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.
Clinical Trials
Study Evaluating CCI-779 in Breast Neoplasms
To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules of orally administered CCI-779 given in combination with daily letrozole, compared to letrozole...
Study Evaluating SKI-606 in Subjects With Breast Cancer
The purpose of this study is to determine if SKI-606 is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer...
The MONET - Study: MR Mammography of Nonpalpable Breast Tumors
The purpose of this study is to determine whether performing MRI of the breast will improve breast cancer management by reducing the number of biopsies and in case of malignancy allowing o...
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
The purpose of this study is to assess if docetaxel and cytoxan can shrink the size of your breast tumor and allow you to preserve your breast or have less extensive surgery on your breast...
The purpose of this study is to determine whether addition of automated whole breast ultrasound to the usual screening mammography in a population of asymptomatic women with mammographical...
PubMed Articles
Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases.
OBJECTIVE: To present the clinicopathological features of metastatic ovarian neoplasms with emphasis in the diagnostic challenge. METHODS: This is a retrospective study including 97 patients with path...
Primary amelanotic melanoma of the breast: combating a rare cancer.
BACKGROUND: Malignant melanoma is the foremost cause of metastasis to the breast from extramammary solid neoplasm. However primary melanoma of the breast is a distinct rarity. Primary melanoma involve...
Lymphoma is a rare neoplasm in the breast. In this location, it may be primary or secondary, depending on whether there is lymphoma elsewhere in the body. The most common presentation of breast lympho...
Non-melanocytic mimics of melanocytic neoplasms.
Bhawan J (2011) Histopathology Non-melanocytic mimics of melanocytic neoplasms Abstract: On histopathologic examination, many non-neoplastic conditions mimic benign or malignant neoplasms. Alternat...
To report an unanticipated pregnancy during ovarian ablation treatment with goserelin (10.8 mg SC every 12 weeks) in a 26-year old female with breast cancer. Review of the current literature and rep...
